ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstracts tagged "risk assessment"

  • Abstract Number: 0993 • ACR Convergence 2022

    SARS-CoV-2 Vaccine Side Effects and Infections in SLE

    Laura Yan1, Arielle Mendel2, Evelyne Vinet2, Fares Kalache3, Jennifer Lee1, Popi Panaritis2 and Sasha Bernatsky1, 1Research Institute of the McGill University Health Centre, Montréal, QC, Canada, 2McGill University Health Centre, Montréal, QC, Canada, 3McGill University Health Center, Montréal, QC, Canada

    Background/Purpose: SLE patients are an especially vulnerable population in the face of the COVID pandemic due to their dysregulated endogenous immune system, further downregulated by…
  • Abstract Number: 1984 • ACR Convergence 2022

    Malignancies Risk in Rheumatoid Arthritis Patients Treated with Tofacitinib or TNF Inhibitors, a National Study: RELATION Study

    jacques-eric gottenberg1, Nadir Mammar2, Meriem Kessouri2, Jeremie RUDANT2, nada Assi3, Fanny raguideau3 and julien kirchgesner4, 1Strasbourg University Hospital, Strasbourg, France, 2Pfizer, Paris, France, 3HEVA, Lyon, France, 4AP-HP, Paris, France

    Background/Purpose: Patients with IMID, and notably patients with rheumatoid arthritis RA, are at increased risk of cancer compared with the general population. It is hence…
  • Abstract Number: 1047 • ACR Convergence 2022

    A Novel Prediction Tool for Progression of Systemic Sclerosis-Interstitial Lung Disease Despite Treatment with Immunosuppression

    Elizabeth Volkmann1, Holly Wilhalme1, Grace Kim1, Jonathan Goldin1, Shervin Assassi2, Masataka Kuwana3, Donald Tashkin1 and Michael roth1, 1University of California Los Angeles, Los Angeles, CA, 2McGovern Medical School, University of Texas, Houston, TX, 3Nippon Medical School Graduate School of Medicine, Tokyo, Japan

    Background/Purpose: Systemic sclerosis-interstitial lung disease (SSc-ILD) is the leading cause of SSc-related death. While some patients respond favorably to treatment with immunosuppression, a subset of…
  • Abstract Number: 2268 • ACR Convergence 2022

    Recurrent Thrombosis Risk in Non-anticoagulated Antiphospholipid Syndrome Patients: A Prospective Case-Control Study from AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”)

    Cecile Yelnik1, Zeynep Belce Erton2, Elodie Drumez3, Dachi Cheildze2, Danieli Castro Oliveira de Andrade4, Ann E Clarke5, Maria G. Tektonidou6, Vittorio Pengo7, Savino Sciascia8, Amaia Ugarte9, H Michael Belmont10, Mª Angeles Aguirre11, Paul fortin12, maria gerosa13, Flavio Victor Signorelli14, Tatsuya Atsumi15, Zhouli Zhang16, Hannah Cohen17, D. Ware Branch18, Denis Wahl19, Laura Andreoli20, Esther Rodriguez Almaraz21, Michelle Petri22, Ricard Cervera23, Yu Zuo24, Bahar Artim-Esen25, Guillermo Pons-Estel26, Rohan Willis27, Maria Laura Bertolaccini28, Robert Roubey29, Doruk Erkan2 and on behalf of APS ACTION On Behalf Of APS ACTION2, 1Lille University, Lille, France, 2Hospital for Special Surgery, New York, NY, 3Université de Lille, Lille, France, 4Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil, 5University of Calgary, Division of Rheumatology, Cumming School of Medicine, Calgary, AB, Canada, 6National and Kapodistrian University of Athens, Athens, Greece, 7Padova University Hospital, Padova, Italy, 8University of Turin, Torino, Italy, 9BioCruces Bizkaia Health Research Institute, Barakaldo, Spain, 10NYU School of Medicine, New York, NY, 11Maimonides Institute for Biomedical Research of Córdoba, Cordoba, Spain, 12CHU de Québec, Pavillon CHUL, Québec, Canada, 13University of Milan, Milano, Italy, 14Universidade do Estado do Rio de Janeiro, Rio De Janeiro, Brazil, 15Hokkaido University, Sapporo, Japan, 16Peking University First Hospital, Beijing, China, 17University College London, London, United Kingdom, 18University of Utah, Salt Lake City, UT, 19Université de Nancy, Nancy, France, 20Rheumatology and Clinical Immunology Unit, ASST Spedali Civili and University of Brescia, Brescia, Italy, 21Hospital Universitario 12 de Octubre, Madrid, Spain, 22Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD, 23Hospital Clínic de Barcelona, Barcelona, Spain, 24University of Michigan, Ann Arbor, MI, 25Istanbul University, Istanbul, Turkey, 26CREAR, Rosario, Argentina, 27University of Texas Medical Branch, Galveston, TX, 28King's College London, London, United Kingdom, 29University of North Carolina, Chapel Hill, NC

    Background/Purpose: Long-term anticoagulation is the standard of care for antiphospholipid syndrome (APS) patients with macrovascular thrombosis. However, in daily practice, long-term anticoagulation may not be…
  • Abstract Number: 1049 • ACR Convergence 2022

    Risk Stratification of Patients with Systemic Sclerosis-associated Pulmonary Arterial Hypertension in EUSTAR Using the Current and New Proposed Criteria

    Hilde Jenssen Bjørkekjær1, cosimo bruni2, PATRICIA E CARREIRA3, Paolo Airò4, CARMEN PILAR SIMEON5, Marie-Elise Truchetet6, Alessandro Giollo7, Alexandra Balbir-Gurman8, Mickaël MARTIN9, Chris Denton10, Armando Gabrielli11, Håvard Fretheim12, Imon Barua12, Helle Bitter13, Øyvind Midtvedt12, Kaspar Broch14, Arne Andreassen12, Yoshiya Tanaka15, Gabriela Riemekasten16, Ulf Müller-Ladner17, Marco Matucci-Cerinic2, Ivan Castellvi18, Elise Siegert19, Eric Hachulla20, Oliver Distler21 and Anna-Maria Hoffmann-Vold12, 1Department of Rheumatology, Hospital of Southern Norway, Kristiansand, Norway, Kristiansand, Norway, 2University of Florence, Florence, Italy, 3HOSPITAL 12 DE OCTUBRE, Madrid, Spain, 4Rheumatology and Clinical Immunology Unit, ASST Spedali Civili, Brescia, Italy, 5Hospital Vall D'Hebron, Barcelona, Spain, 6CHU de Bordeaux, Bordeaux, France, 7Rheumatology Section, Department of Medicine, University of Verona, Italy, Verona, Italy, 8Rheumatology Institute, Rambam Health Care Campus, Haifa, Israel, 9Poitiers's Universatory Hospital, Department of Internal Medicine, Poitiers, France, Mignaloux-Beauvoir, France, 10University College London, London, United Kingdom, 11Università Politecnica delle Marche, Ancona, Italy, 12Oslo University Hospital, Oslo, Norway, 13Sorlandet sykehus, Kristiansand, Norway, 14Oslo University Hospital, Rikshospitalet, Department of Cardiology, Oslo, Norway, Oslo, Norway, 15University of Occupational and Environmental Health, Kitakyusyu Fukuoka, Japan, 16University Clinic Schleswit-Holstein (UKSH), Luebeck, Germany, 17JLU Campus KK, Bad Nauheim, Germany, 18Hospital Universitari de la Santa Creu i Sant Pau, Vilafranca del Pened, Spain, 19Charité Hospital, Berlin, Germany, 20University of Lille, LILLE, France, 21Department of Rheumatology, University Hospital Zurich, University of Zurich, Zürich, Switzerland

    Background/Purpose: Pulmonary arterial hypertension (PAH) is a major clinical challenge in systemic sclerosis (SSc). A new definition for precapillary PH is proposed. Risk stratification is…
  • Abstract Number: 1249 • ACR Convergence 2022

    Short-term Variations in Subchondral Tibial Bone Texture of Conventional X-Rays Predicts Knee Osteoarthritis Progression

    Ahmad Almhdie-Imjabbar1, Hechmi TOUMI2, Zineb ZERZOUF3 and Eric LESPESSAILLES4, 1University of Orleans / CHR Orleans, France, Orleans, Centre, France, 2Regional hospital centre of Orleans, France, Orleans, France, 3University of Tours, Tours, France, 4Regional hospital centre of Orleans, France, ORLEANS, Centre, France

    Background/Purpose: Early detection and assessment of Knee Osteoarthritis (KOA) prognostic factors are crucial for developing management and treatments that aim at prevention of irreversible damage…
  • Abstract Number: 0084 • ACR Convergence 2022

    Facilitators and Barriers of Vaccine Uptake in Patients with Chronic Inflammatory Rheumatic Disease: A Scoping Review

    Silke Neusser1, Anja Neumann1, Christian Speckemeier1, Pauline zur NIeden1, Sarah Schlierenkamp1, Anke Walendzik1, Ute Karbach2, Ioana Andreica3, Kristina Vaupel4, Xenofon Baraliakos5 and Uta Kiltz4, 1Essener Forschungsinstitut für Medizinmanagement, Essen, Germany, 2Institute of Medical Sociology, Health Services Research and Rehabilitation Science (IMVR), Cologne, Germany, 3Rheumazentrum Ruhrgebiet, Ruhr-Universität-Bochum, Herne, Germany, 4Rheumazentrum Ruhrgebiet, Herne, Germany, 5Rheumazentrum Ruhrgebiet Herne, Herne, Germany

    Background/Purpose: Patients with chronic inflammatory rheumatic diseases (CIRD) remain underrepresented in receiving vaccinations despite being disproportionately affected by infectious complications. The aim of our study…
  • Abstract Number: 1342 • ACR Convergence 2022

    Quality Improvement: Communicating Risk Regarding JAK Inhibitor Use in Rheumatology Patients

    Reid Weisberg1, Brett Capel1, Annabelle Guo1, Komal Patel1, Rashmi Arora2, Swathi Reddy3 and Una Makris4, 1University of Texas Southwestern Medical Center, Dallas, TX, 2Dallas VA Medical Center / University of Texas Southwestern Medical Center, Dallas, TX, 3Dallas VA Medical Center / University of Texas Southwestern Medical Center, Colleyville, TX, 4UT Southwestern Medical Center and Dallas VA, Dallas, TX

    Background/Purpose: In September 2021, the FDA updated its boxed warnings for Janus Kinase (JAK) inhibitors to include increased risk of major adverse cardiac events (MACE)…
  • Abstract Number: 0205 • ACR Convergence 2022

    Virtually Training Peer Coaches to Use Motivational Interviewing Skills: Processes from a Rheumatoid Arthritis Intervention Training Program

    Mackenzie Brown1, Yuliana Domínguez Páez2, Assem Jabri3, Geyanne Lui4, Joan Weiner3, Aberdeen Allen5, Tien Sydnor-Campbell6, Shelley fritz3, Megan Creasman7, Shanthini Kasturi8, Monika Safford3 and Iris Navarro-Millan3, 1Weill Cornell Medicine, Brooklyn, NY, 2Weill Cornell Medicine, Bronx, NY, 3Weill Cornell Medicine, New York, NY, 4Albert Einstein College of Medicine, New York, NY, 5Weill Cornell Medicine, Parlin, 6Weill Cornell Medicine, Philedelphia, 7NYP-Weill Cornell, New York, NY, 8Tufts Medical Center, Boston, MA

    Background/Purpose: Peer coaching interventions are effective in helping individuals with chronic conditions understand and manage their disease. Most peer coach training programs occur in person,…
  • Abstract Number: 1365 • ACR Convergence 2022

    Adverse Events Associated with Belimumab Use in Pediatric Patients: Review and Analyses of the FDA Adverse Event Reporting System Database

    Ivone Kim, Debra Ryan, Carmen Cheng and Cindy Kortepeter, Food and Drug Administration, Silver Spring, MD

    Background/Purpose: FDA approved belimumab, the first targeted biological treatment for SLE, in March 2011 for adults with active, seropositive SLE receiving standard therapy. The indicated…
  • Abstract Number: 0262 • ACR Convergence 2022

    Predictors of Fragility Fracture Amongst Patients with Rheumatoid Arthritis: An Observational Cohort Study

    Seema Sharma1 and Marwan Bukhari2, 1Lancaster Royal Infirmary, Lancaster, United Kingdom, 2University Hospitals of Morecambe Bay NHS Trust, Lancaster, United Kingdom

    Background/Purpose: Rheumatoid arthritis (RA) is associated with reduced bone mineral density and almost one third of this population have osteoporosis leading to increased risk of…
  • Abstract Number: 1389 • ACR Convergence 2022

    The New Serum Synovial Biochemical Marker HELIX-III Predicts Radiological Progression in Early Arthritis Independently of Usual Risk Factors

    Patrick Garnero1, Evelyne Gineyts1, Jean-Charles Rousseau1, Pascal Richette2, Jérémie SELLAM3 and Roland Chapurlat1, 1INSERM 1033, Lyon, France, 2Department of Rheumatology, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, Paris, France, 3Sorbonne Universite, AP-HP, Saint-Antoine hospital, Paris, France

    Background/Purpose: The prognosis of rheumatoid arthritis (RA) is highly variable across patients (P.) and difficult to predict. Usual risk factors, e.g., radiological joint damage, increased…
  • Abstract Number: 0292 • ACR Convergence 2022

    Malignancy in the Upadacitinib Clinical Trial Programs for Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis

    Andrea Rubbert-Roth1, Adriana Kakehasi2, Tsutomu Takeuchi3, Marc Schmalzing4, Hannah Palac5, Jianzhong Liu5, Samuel Anyanwu5, Ralph Lippe6 and Jeffrey Curtis7, 1Division of Rheumatology, Cantonal Clinic St Gallen, St.Gallen, Switzerland, 2Federal University of Minas Gerais, Hospital das Clínicas, Belo Horizonte, Brazil, 3Keio University and Saitama Medical University, Tokyo, Japan, 4University Hospital Wuerzburg, Wuerzburg, Germany, 5AbbVie, Inc., North Chicago, IL, 6AbbVie, Inc, Wiesbaden, Germany, 7University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose: Increased risk of malignancies has been associated with chronic inflammation, as well as immunosuppressive and immunomodulatory therapies. The objective of this analysis is to…
  • Abstract Number: 1396 • ACR Convergence 2022

    Risk of Hospitalized Infections in Older Elderly Rheumatoid Arthritis Patients Treated with Biological/Targeted Synthetic DMARDs: Evaluation Using Data from a Japanese Claims Database

    Masayoshi Harigai1, Takao Fujii2, Ryoko Sakai3, Ataru Igarashi4, Ayako Shoji5, Hiroko Yamaguchi6, Katsuhiko Iwasaki6, Misako Makishima7, Amika Yoshida7, Norihiro Okada7, Katsuhisa Yamashita7 and Yutaka Kawahito8, 1Division of Rheumatology, Department of Internal Medicine, Tokyo Women’s Medical University School of Medicine, Tokyo, Japan, 2Department of Rheumatology and Clinical Immunology, Wakayama Medical University, Wakayama, Japan, 3Department of Public Health and Epidemiology, Meiji Pharmaceutical University, Tokyo, Japan, 4Department of Health Economics & Outcomes Research, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan; Unit of Public Health and Preventive Medicine, Yokohama City University of Medicine, Kanagawa, Japan, 5Medilead Inc., Tokyo, Japan; Department of Health Economics and Outcomes Research, Graduate School of Pharmaceutical Sciences, University of Tokyo, Tokyo, Japan; Healthcare Consulting Inc., Tokyo, Japan, Shinjuku-ku, Japan, 6Medilead Inc., Tokyo, Japan, Shinjuku-ku, Japan, 7Chugai Pharmaceutical Co., Ltd., Chuo-ku, Tokyo, Japan, 8Inflammation and Immunology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan, Kyoto, Kyoto, Japan

    Background/Purpose: Safety evidence of biological or targeted synthetic DMARDs (b/tsDMARDs) is still insufficient in older elderly ( >=75 years old (y/o)) patients with rheumatoid arthritis…
  • Abstract Number: 0510 • ACR Convergence 2022

    MACE and VTE Across Upadacitinib Clinical Trial Programs in Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis

    Christina Charles-Schoeman1, Ernest Choy2, Iain B McInnes3, Eduardo Mysler4, Peter Nash5, Kunihiro Yamaoka6, Ralph Lippe7, Nasser Khan8, Anna K Shmagel9, Hannah Palac9, Jessica Suboticki10 and Jeffrey Curtis11, 1Division of Rheumatology, University of California, Los Angeles, Santa Monica, CA, 2Division of Infection and Immunity, CREATE Centre, Cardiff University, Cardiff, Wales, United Kingdom, 3Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, Scotland, United Kingdom, 4Department of Rheumatology, OMI (Medical Research Organization), Buenos Aires, Argentina, 5School of Medicine, Griffith University, Sunshine Coast, Australia, 6Department of Rheumatology and Infectious Diseases, Kitasato University School of Medicine, Kanagawa, Japan, 7AbbVie, Inc, Wiesbaden, Germany, 8AbbVie, Inc., Abbott Park, IL, 9AbbVie, Inc., North Chicago, IL, 10AbbVie, Inc., Mettawa, IL, 11Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose: Patients with untreated immune-mediated inflammatory diseases, such as RA, PsA, and AS, are at increased risk for major adverse cardiovascular events (MACE) and venous…
  • 1
  • 2
  • 3
  • …
  • 6
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences